Wednesday, January 19, 2022

Here’s to why Indian Globalization Capital Inc. (IGC) stock moves up during after-hours trading?

Indian Globalization Capital Inc. (NASDAQ: IGC) stock gained by 4.07% at last close while the IGC stock price surged further by 3.91% in the after-hours trading. India Globalization Capital is involved in the research and making of cannabinoid-based treatments for medical use. Presently, the corporation has two business units: life sciences and infrastructure.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


IGC stock’ Current Development

India Globalization Capital has released preliminary findings for its Phase 1 IGC-AD1 clinical trial’s exploratory endpoints. IGC-AD1 is an unique marijuana-based investigational novel medication candidate for Alzheimer’s disease patients. The Phase 1 clinical trial yielded valuable information on pharmacokinetics (PK) and genotyping, which will be crucial in understanding optimal dosing in subsequent trials, pending FDA approval.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


On December 1, 2021, the clinical study outcomes were posted to the FDA in the form of a Clinical/Statistical Report (“CSR”). Furthermore, data from the secondary endpoints, neuropsychiatric symptoms in Alzheimer’s patients, and other pertinent data are available on a Form 8-K filed with the Securities and Exchange Commission on December 2, 2021, as previously stated.

Nearly 50 million people around the globe are affected by Alzheimer’s disease, with women accounting for roughly 66 percent of those affected (alz.org). Sadly, there is no treatment for Alzheimer’s disease, and there are no FDA-approved medications to treat many of the signs and symptoms, particularly agitation.

About Pharmacokinetics,

Pharmacokinetics is the study of how long it takes for a drug to be absorbed, processed, metabolised, and eliminated by the body after it has been given. Considering how much time a medicine will take to yield the required effects and when those effects fade can aid in determining the most appropriate and safe dose frequency.

Final results obtained show that,

Pharmacokinetics data suggest that administering two or three times per day may be appropriate for patients because the first and perhaps second doses would be removed from the body before future doses.

However, pending FDA permission, the genotyping findings will be used to guide the design of Phase 2 and Phase 3 clinical trials. IGC-AD1 is an experimental novel medicine that has not been approved by any regulatory agency in any nation as a treatment. Despite the fact that the Phase 1 trial was completed and some data was obtained, IGC-safety, AD1’s tolerability, and efficacy must be confirmed in bigger and more disparate groups of Alzheimer’s patients.

Latest news

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721...

Best cannabis stock investment could lead to great profits in the near future

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal,...

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading...

CNFinance Holdings Ltd. (CNF) stock fell during after-hours, despite any current update.

CNFinance Holdings Ltd. (NASDAQ: CNF) stock declined by 20.27% in the after-hours trading session. CNFinance Holdings Limited is a significant provider of home equity...

Related news

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721...

Best cannabis stock investment could lead to great profits in the near future

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal,...

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading...

CNFinance Holdings Ltd. (CNF) stock fell during after-hours, despite any current update.

CNFinance Holdings Ltd. (NASDAQ: CNF) stock declined by 20.27% in the after-hours trading session. CNFinance Holdings Limited is a significant provider of home equity...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam